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Primary Care, University of Cambridge, Institute of Public Health, Forvie Site, Robinson Way, Cambridge, UKBackground & Aims: Increasing age is associated with impaired Conclusions: CD4+ T-lymphocyte telomere length, independent
immune function and in chronic HCV infection speciﬁcally, with
progressive ﬁbrosis, liver failure, HCC and impaired responses
to antiviral therapy. T-lymphocyte telomere length declines with
age. We hypothesised that shorter T-lymphocyte telomere length
would be associated with poor clinical outcome in HCV infection.
Methods: Circulating T-lymphocyte telomere length, an objective
measure of immune senescence, was measured by ﬂow-FISH in
135 HCV-RNA-positive, treatment-naïve patients and 41 healthy
controls in relation to clinical outcome.
Results: Shorter CD4+CD45RO+ T-lymphocyte telomeres were
associated with severe ﬁbrosis (p = 0.003), independent of male
sex (p = 0.04), CMV positivity (p = 0.003), previous HBV infection
(p = 0.007), and age (p = ns) in viraemic patients compared to
controls. There were inverse correlations between CD4+CD45RO+
telomere length and ﬁbrosis stage (p <0.001), portal tract inﬂam-
matory grade (p = 0.035), prothrombin time (p <0.001) and biliru-
bin (p = 0.001). One hundred and twenty-four viraemic
individuals were followed prospectively to a composite endpoint
of death, hepatic decompensation or HCC. Independent of age,
those with shorter CD4+CD45RO+ telomeres were less likely to
be complication free after 2-years than those with longer telo-
meres (86% versus 96%, p = 0.009) with an age-adjusted hazard
ratio of 0.93 (0.90–0.96). In addition, CD4+CD45RO+ telomere
length predicted successful antiviral therapy (p = 0.001) indepen-
dent of other factors.Journal of Hepatology 20
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Chronic hepatitis C virus (HCV) infection may lead to cirrhosis
and hepatocellular carcinoma (HCC). Prospective cohort studies
demonstrate that the majority of viraemic individuals never
develop severe hepatic ﬁbrosis [1,2]; factors associated with pro-
gressive ﬁbrosis include male sex, obesity and concurrent alcohol
misuse [3]. Several groups have demonstrated that long-term
prognosis in HCV infection is critically dependent upon age at
acquisition [3–6].
Human ageing is associated with impaired adaptive immunity
[7,8] with reduced numbers of naïve cells, increased numbers of
antigen-experienced cells and oligoclonal expansion of CD8+ T-
lymphocytes. Prospective studies demonstrate that these changes
predict morbidity and mortality in healthy elderly populations,
leading to the concept of an ‘immune risk’ phenotype [8–10].
Progressive shortening of lymphocyte telomeres is character-
istic of immune senescence and may underpin changes in lym-
phocyte function [11]. Telomeres are repeating sequences of
DNA at the extreme ends of eukaryotic chromosomes. DNA poly-
merase cannot transcribe to the chromosomal tip; thus telomeres
shorten with each cell division, leading eventually to a DNA dam-
age signal mediated by c-H2AX, p53 and p16INK4A [12,13] pre-
venting further mitoses [14], a point deﬁned as replicative
senescence. In healthy elderly subjects, shortened lymphocytic
telomeres were associated with increased mortality, particularly
after infection [9].
Chronic viral infections accelerate immune senescence and
declining immune function [15,16]. Cytomegalovirus (CMV)
infection is implicated in accelerated immune senescence within
both CMV-speciﬁc and non-speciﬁc lymphocytes [17] and is asso-
ciated with oligoclonal expansion of CD4+ and CD8+ lymphocytes10 vol. 53 j 252–260
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in elderly populations [18]. Oligoclonality of CD8+ lymphocytes
in HCV infection is associated with increased ﬁbrosis and reduced
responses to antiviral therapy [19]. Kitay-Cohen et al. demon-
strated that viraemic HCV is associated with short peripheral leu-
cocyte telomeres, although no relation to clinical or treatment
outcome was explored [20].
The marked effect of age on the natural history of HCV infec-
tion and the response to antiviral therapy is unexplained [21,22].
This study addresses the relation between lymphocyte telomere
length, age and clinical outcome in chronic HCV infection.
Materials and methods
HCV infected patients recruited at Addenbrooke’s Hospital, Cambridge gave writ-
ten informed consent with approval of the Local Research Ethics Committee.
Patients co-infected with HIV, HBV or other chronic liver disease, identiﬁed by
history, blood tests or liver biopsy, were excluded. Lymphocytes from healthy
controls were obtained from local volunteers; none gave a history of chronic ill-
ness or intravenous drug usage. Study subject groups were deﬁned as: healthy
controls; viraemic with mild disease (Ishak ﬁbrosis 0–3); viraemic with severe
disease (Ishak ﬁbrosis 4–6) (Table 1).
IgG antibody against CMV was sought by chemiluminescent immunoassay
(Diasorin, Saluggia, Italy). Anti-HCV IgG was sought by ADVIA Centaur sandwich
immunoassay (Bayer, Tarrytown, NY); HCV-RNA by real-time taqman PCR assay
targeting the conserved 50 non-coding region on a Rotor-gene™ 3000 instrument
(Corbett Lifescience, Sydney, Australia). Probit analysis (Stats Direct, www.stats-
direct.com) revealed a lower limit of detection of 25 IU/ml (6.3–38.6, 95% conﬁ-
dence intervals). Patients with anti-HCV were deﬁned as viraemic if HCV-RNA
was detected on all 3 occasions at 6-month intervals; only those with a liver
biopsy within 2 years of study entry were included. Those with inconsistent
HCV-RNA results were excluded. All subjects were treatment-naïve at enrolment
and none had evidence of current or previous hepatic decompensation or HCC.
Less than 20% of HCV-infected subjects had a known, single time of infection;
thus duration of infection was unavailable.
Liver biopsies were scored according to Ishak criteria by a specialist liver hist-
opathologist (SED), blinded to the lymphocyte studies or outcome. Histologic
activity index represented the sum of interface hepatitis (scored 0–4), conﬂuent
necrosis (0–6), lobular inﬂammation (0–4) and portal tract inﬂammation (0–4).
Fibrosis was staged 0 (absent) to 6 (cirrhosis). Steatosis was scored 0–3.
A subgroup of patients was treated subsequently with peg-IFN-a2a and riba-
virin (RBV) (Roche, Welwyn Garden City, UK). All patients received 180 mcg of
peg-IFN-a2a sub-cutaneously once weekly, with subsequent dose-alterations dic-
tated by clinical and laboratory parameters and RBV (800 mg daily for genotype 2Table 1. Demographic characteristics of subjects in the three study groups.
Healthy Controls HCV-RN
n 41 73
Age (years, mean ± SD) 47.0 ± 11.1 49.4 ± 1
Sex (% male) 51.2 71.2
BMI (mean ± SD) 26.8 ± 3.5 25.6 ± 4
Source of HCV:
IDU% 58.9
Blood products% 15.1
Unknown% 26.0
% IgG anti-HBc positive 12.2 26.0
% CMV antibody positive 26.8 49.3
Biochemical indices
Bilirubin (lmol/L, mean ± SD) - 9.9 ± 5.1
ALT (IU/L, mean ± SD) - 95.5 ± 8
PT (seconds, mean ± SD) - 12.5 ± 0
Ishak score
Interface hepatitis (0 - 4) - 1.1 ± 0.8
Conﬂuent necrosis (0 - 6) - 0.0 ± 0.2
Lobular hepatitis (0 - 4) - 1.8 ± 0.6
Portal inﬂammation (0 - 4) - 1.8 ± 0.7
Fibrosis (0 - 6) - 1.8 ± 0.9
Steatosis (0 – 3) - 0.5 ± 0.7
Bold indicates signiﬁcant results.
Kruskal–Wallis unless otherwise stated: 1Chi-squared. 2Mann–Whitney U Test.
Journal of Hepatology 201or 3 or weight-based between 1000 and 1200 mg for genotype 1 or 4). Patients
with genotype 1 or 4 were treated for 12 weeks and then a further 36 weeks if
they were HCV-RNA negative or had undergone a 2 log10 drop in viral load com-
pared to baseline. Those with genotype 2 or 3 infection were treated for 24 weeks.
All subjects underwent HCV-RNA testing six months after cessation of therapy to
determine if they had achieved sustained virological response (SVR). No patient
received growth factors to support haematological parameters. Patients unable
to tolerate antiviral therapy on symptomatic grounds were excluded from
analysis.
A composite endpoint was used for outcome analysis: outcome events were
death, ﬁrst episode of hepatic decompensation (new rise in bilirubin to twice the
upper limit of normal, development of ascites, hepatic encephalopathy, portal
hypertensive haemorrhage) or development of hepatocellular carcinoma. Out-
come was determined from study entry and survivors were censored at last clinic
appointment.Lymphocyte preparation
Peripheral blood mononuclear cells (PBMCs) were obtained by centrifugation of
citrated blood over Lymphoprep (Nycomed, Roskilde, Denmark) and analysed
immediately or cryopreserved at 80 C in 80% foetal calf serum (Biosera, East
Sussex, UK), 10% RPMI-1640 (Gibco, Paisley, UK) and 10% dimethyl sulphoxide
(DMSO) (Sigma–Aldrich, Gillingham, UK).Flow cytometry
Flow-cytometric analysis of T-lymphocytes was performed using combinations of
the following: CD4-biotin (Beckman Coulter, Fullerton, CA), CD4-PE-Cy5, CD8-
biotin, CD8-PE-Cy5, CD27-APC, CD57-biotin (all BD, San Diego, CA), CD45RO-bio-
tin (Ebiosciences, San Diego, CA), CD45RO-FITC (Dako, Glostrup, Denmark).
Biotinylated antibodies were followed by streptavidin-Cy3 (Cedarlane laborato-
ries, Ontario, Canada). All cytometry was performed on a FACScalibur analyser
(BD) unless otherwise stated; data were analysed with FCSpress software
(www.fcspress.com).
Telomere length by ﬂow cytometry
Telomere length of CD4+ or CD8+ T-cells was measured using 3-colour ﬂow-FISH
assay as described [23,24]. CD4+ PBMCs from one healthy individual were ana-
lysed in every experiment as an internal control. Lymphocyte telomere length
within an individual is expressed as mean ﬂuorescence intensity (MFI). Inter-
experimental standard deviation for the same sample was 1.2% and 0.9% for
CD4+ and CD8+ lymphocytes, respectively.A positive mild HCV-RNA positive severe p value
62
1.2 53.2 ± 7.2 0.002
77.4 0.121
.3 27.2 ± 5.6 0.19
67.7 0.401
8.1
24.2
32.3 0.0041
58.1 0.0071
14.3 ± 10.1 0.0092
8.7 109.1 ± 66.4 0.022
.8 13.8 ± 1.7 <0.00012
1.9 ± 0.6 <0.00012
0.0 ± 0.2 0.932
2.2 ± 0.6 0.00072
2.3 ± 0.5 0.00012
4.8 ± 0.7 <0.00012
0.9 ± 0.9 0.0022
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Statistics
Population data were subjected to non-parametric analysis, with lymphocyte
surface phenotype analysed by Kruskal–Wallis. Ishak scores are non-linear
variables and therefore, associative data were analysed by Spearman’s Rank cor-
relation coefﬁcient. Univariate analysis of survival was performed by the Kaplan–
Meier method; curves were compared with the log-rank method and hazard
ratios constructed from a Cox regression analysis (Prism 5.0, Graphpad, San
Diego, CA).A
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Fig. 1. Telomere length of CD8+ and CD4+ T-cells from healthy controls and HCV-inf
telomere length. Left: Live lymphocyte gate by light-scatter characteristics. Centre: Iden
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Kruskal–Wallis with Dunn’s multiple comparison test; bars show p <0.05.
254 Journal of Hepatology 201Backward stepwise multinomial regression analysis was performed to iden-
tify predictors of severe ﬁbrosis using SPSS 15.0 for Windows, with allocation
to the severe ﬁbrosis group (Ishak ﬁbrosis stage 4–6) as outcome. Input variables
were gender, IgG anti-CMV status, age, BMI, IgG anti-HBc status, CD4+CD45RO+
telomere length and CD8+CD45RO+ telomere length.
To study factors associated with SVR, logistic regression analysis was per-
formed using SPSS 15.0 for Windows, with SVR as outcome. Input variables were
age, sex, CMV antibody status, HCV genotype, Ishak ﬁbrosis score, body mass
index (BMI), CD8+CD45RO+ and CD4+CD45RO+ telomere length.CD4 
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Table 2. Predictors of severe ﬁbrosis (Ishak ﬁbrosis 4–6) by backward stepwise multinomial regression. Input variables were gender, previous CMV or HBV, age, BMI,
CD4+CD45RO+ telomere length, and CD8+CD45RO+ telomere length. Variables associated with severe ﬁbrosis (p <0.1) in simple linear regression were included in a
multiple regression analysis.
Variable Simple multinomial regression Backward stepwise multinomial regression
b SE df OR (95% CI) p b SE df OR (95% CI) p
Male gender 0.89 0.44 1 2.43 (1.03, 5.74) 0.043 1.04 0 .50 1 2.84 (1.07, 7.53) 0.04
CMV+ 1.33 0.44 1 3.78 (1.61, 8.83) 0.002 1.43 0 .48 1 4.18 (1.63, 10.73) 0.003
Age 0.07 0.02 1 1.08 (1.03, 1.12) 0.001
BMI 0.02 0.04 1 1.02 (0.94, 1.10) 0.71
Anti-HBc+ 1.65 0.54 1 5.20 (1.80, 15.1) 0.002 1.58 0 .58 1 4.74 (1.53, 14.72) 0.007
CD4+CD45RO+ telomere length 0.05 0.01 1 1.05 (1.02, 1.08) 0.001 0.04 0 .01 1 1.05 (1.02, 1.78) 0.003
CD8+CD45RO+ telomere length 0.03 0.01 1 1.03 (1.01, 1.06) 0.002
Bold indicates signiﬁcant results.
JOURNAL OF HEPATOLOGYOnly variables with a p value of <0.10 on univariate analysis were subjected
to multi-variate analysis. p values of <0.05 were considered signiﬁcant.Results
T-lymphocyte telomere length, viraemia and ﬁbrosis stage (Fig. 1)
Increasing age was associated with shortened CD4+ T-lympho-
cyte telomeres in healthy subjects (p = 0.015, Rs = 0.379) andTe
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Journal of Hepatology 201HCV-infected groups (p <0.0001, Rs = 0.415). Study subjects
were recruited according to HCV RNA status and hepatic ﬁbrosis
stage, so there were predictable differences between patient
groups and controls with respect to CMV and IgG anti-HBc status
(Table 1) and within patient groups for age. Both CD4+CD45RO+
and CD8+CD45RO+ T-cell telomere length were signiﬁcantly
shorter in HCV-infected subjects with severe ﬁbrosis compared
to controls and subjects with mild ﬁbrosis.
To study the independent association between lymphocyte
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100
150
200
p = 0.035
Rs = - 0.207
Ishak portal inflammation grade
1 2 3
Te
lo
m
er
e 
M
FI
Te
lo
m
er
e 
M
FI
CD4+CD45RO+
n = 133 
50
100
150
200
p <0.0001
Rs = - 0.340
Ishak fibrosis stage
0 1 2 3 4 5 6
D45RO+ lymphocytes from 133 viraemic HCV subjects with (A and B) ﬁbrosis
an and inter-quartile range; correlation by Spearman’s Rank.
0 vol. 53 j 252–260 255
Research Article
mial regression model was constructed to determine which fac-
tors were predictive of severe ﬁbrosis. Input variables into the
model were gender, IgG anti-CMV status, age, BMI, IgG anti-
HBc status, CD4+CD45RO+ telomere length and CD8+CD45RO+
telomere length.
Backward stepwise multinomial regression demonstrated
that male sex (OR; 95% CI; p value) (2.84 (1.07, 7.53);
p = 0.04), CMV positivity (4.18 (1.63, 10.73); p = 0.003), anti-
HBc positivity (4.74 (1.53, 14.72); p = 0.007) and decreasing
CD4+CD45RO+ telomere length (1.05 (1.02, 1.78); p = 0.003)
were independently associated with severe HCV-related ﬁbrosis
(Table 2).
Age and CD8+CD45RO+ telomere length showed signiﬁcant
association on simple regression analysis with severe ﬁbrosis,
but no independent association in backward stepwise regression
analysis.
Telomere length and cells with ‘advanced phenotype’
There were no differences in the proportion of CD4+ T-cells that
were CD27+CD45RO (p = 0.07), CD27+CD45RO+ (p = 0.14) or
CD27CD45RO+ (p = 0.44). Nor were there differences between
the three groups in the proportion of CD8+ T-cells that were
CD27+KLRG1CD57 (Kruskal–Wallis, p = 0.21), KLRG1+CD57
(p = 0.48), or KLRG1+CD57+ (p = 0.58). Thus, shortened telomeres
in chronic HCV infection were not attributable to accumulation of
lymphocytes with ‘advanced phenotype’.p = 0.002
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256 Journal of Hepatology 201Circulating lymphocyte telomere length, ﬁbrosis, and portal
inﬂammation (Fig. 2)
The relation between CD4+ or CD8+ lymphocyte telomere length
and histology was investigated in 133 viraemic patients.
CD4+CD45RO+ lymphocyte telomere length correlated with
ﬁbrosis stage (p <0.001, Fig. 2B), portal tract inﬂammation grade
(p = 0.035) and conﬂuent necrosis (p = 0.036), but there was no
evidence of correlation with interface hepatitis (p = 0.34), lobular
hepatitis (p = 0.84) or steatosis (p = 0.76). CD8+CD45RO+ lympho-
cyte telomere length also correlated with ﬁbrosis stage
(p <0.001), portal tract inﬂammatory grade (p = 0.027) and con-
ﬂuent necrosis (p = 0.039), but showed no evidence of correlation
with interface hepatitis (p = 0.125), lobular hepatitis (p = 0.504)
or steatosis (p = 0.706).
Lymphocyte telomere length and clinical parameters (Fig. 3)
The relation between CD4+ or CD8+ lymphocyte telomere length
and clinical severity was investigated in 133 viraemic patients.
There was a correlation between CD4+CD45RO+ telomere length
and bilirubin (p <0.001), prothrombin time (p = 0.001) but not
ALT (p = 0.08). There was also a correlation between
CD8+CD45RO+ telomere length and bilirubin (p = 0.002), pro-
thrombin time (p = 0.004), but not with serum ALT (p = 0.12).
These correlations remained signiﬁcant after exclusion of outly-
ing values.14 16 18
in time (secs)
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nds), and right panels, serum alanine transaminase (ALT) (IU/L).
0 vol. 53 j 252–260
JOURNAL OF HEPATOLOGY
Short CD4+ lymphocyte telomere length and poor clinical outcome
(Fig. 4 and Table 3)
Eleven patients were lost to follow-up. The remaining 124 virae-
mic subjects (without previous decompensation or elevated bili-
rubin) were followed prospectively for a median 724 days (IQR:
533–906). The cohort was divided into telomere length that
was longer or shorter than the cohort median (111.9 for
CD4+CD45RO+ and 118.8 for CD8+CD45RO+).
The proportion free of complication at 2 years was 96% and
86% for longer and shorter CD4+CD45RO+ telomeres, respectively
(p = 0.009); and 94% and 88% for longer and shorter
CD8+CD45RO+ telomeres, respectively (p = 0.039). Utilising a
proportional hazards model to investigate telomere length as a
predictor of outcome, independent of age, demonstrated that a
single point increase in CD4+CD45RO+ telomere MFI was associ-
ated with a HR of 0.93 (0.91–0.96) and 0.96 (95% CI: 0.93–0.99) in
the CD8+CD45RO+ subset.
The ﬁndings were more marked when the analysis was
restricted to viraemic subjects with severe ﬁbrosis (n = 55, med-
ian follow-up 742 days (333–913 days) using cohort medians of
108.3 and 116.1, respectively); the proportion free of complica-
tions at 2 years was 97% and 70% for longer and shorter
CD4+CD45RO+ telomeres, respectively (p < 0.001) and 86% and
80% for longer and shorter CD8+CD45RO+ telomeres, respectivelydays to event
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Fig. 4. Clinical outcome of viraemic subjects (n = 124) (A and B) or viraemic patients w
longer (dashed line) or shorter (solid line) than the median. Kaplan–Meier analys
CD8+CD45RO+ telomere length and (B and D) CD4+CD45RO+ telomere length. CD4+C
with each outcome independently: (E) Development of HCC; (F) Episode of decomp
Journal of Hepatology 201(p = 0.27). The age-adjusted HRs for CD4+CD45RO+ and
CD8+CD45RO+ telomeres and the development of the composite
outcome were 0.93 (0.90–0.96) (p = 0.02) and 0.96 (0.93–0.99)
(p <0.001), respectively.
Analysis of each outcome independently in those with severe
ﬁbrosis (n = 55) revealed that longer CD4+ telomere length was
associated with reduced evolution to HCC [p = 0.003, HR 0.92
(0.87–0.97)] and fewer episodes of hepatic decompensation
[p = 0.003, HR 0.93 (0.89–0.98)]. No separate outcome was asso-
ciated with shorter CD8+CD45RO+ telomere length: HCC
(p = 0.1); decompensation (p = 0.05); death (p = 0.95) in those
with severe ﬁbrosis (data not shown).
CD4+ telomere length as either a categorical (Fig. 4) or a con-
tinuous variable (Table 3) was related to the subsequent clinical
course, independent of age and ﬁbrosis stage.
Baseline T-lymphocyte telomere length was related to SVR (Fig. 5 and
Tables 4 and 5)
85 individuals (Table 4) treated with IFN-a and RBV were fol-
lowed to 6 months after completing treatment; 38 subjects
(45%) achieved SVR. Baseline CD4+CD45RO+ telomere length
was longer in those achieving SVR compared to those who
remained viraemic: 119.0 (107.8–126.8) and 105.5 (99.4–
114.2), respectively (p <0.001).ibrosis
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Similarly, CD8+CD45RO+ telomere length was signiﬁcantly
longer in those achieving SVR compared to those who did not:
128.1 (113.4–142.3) and 112.5 (104.5–118.2), respectively
(Mann–Whitney, p < 0.001). There was no clear association
between CD8+CD45RO+ or CD4+CD45RO+ telomere length and
either viral load or viral genotype (Supplementary Fig. 1).
A multi-variate model was constructed to investigate whether
baseline T-lymphocyte telomere length predicted SVR, indepen-
dent of other factors known to predict treatment success. Input
variables included age, sex, viral load, HCV genotype, Ishak ﬁbro-
sis score, body mass index (BMI) and CD8+CD45RO+ or
CD4CD45RO+ telomere length. The outcome measure was SVR.
Utilising backwards stepwise regression to remove non-sig-
niﬁcant variables viral load (p = 0.02) and CD4+CD45RO+ telo-
mere length (p = 0.001) were associated independently with
SVR. For each one point increase in CD4+CD45RO+ lymphocyte
telomere MFI the odds ratio of SVR was 1.08 (1.03–1.13).CD8+CD45RO+
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Fig. 5. Baseline T-lymphocyte telomere length in (A) CD8+CD45RO+ and (B)
CD4+CD45RO+ subsets in relation to SVR (n = 85) following peg-IFNa and RBV.
Analysis by Mann–Whitney U test.
258 Journal of Hepatology 201Discussion
T-lymphocyte telomeres shortened with age in all groups, as
anticipated [11]. T-cells from patients exposed to HCV had telo-
meres that were shorter than matched healthy controls with an
overall difference in telomere length equivalent to 10-years addi-
tional ageing. The changes in T-cell telomere length were even
more marked in those with severe ﬁbrosis, equivalent to 15-years
additional ageing. The ﬁndings associated with HCV infection
were independent of factors known to inﬂuence immune senes-
cence, including age, sex and CMV status. The changes were sim-
ilar in both CD4+ and CD8+ T-lymphocytes, but the important
association was between CD4+ telomere length and severe ﬁbro-
sis. The apparent associations of CD8+ telomere length were due
to their signiﬁcant association with CD4+ telomere length (Sup-
plementary Fig. 2). Importantly, by including age and telomere
length in the three analyses of hepatic ﬁbrosis progression, clin-
ical outcome and treatment outcome, it is clear that telomere
length is a signiﬁcant predictor of all three, independent of
patient age.
An important relation between immune senescence and clin-
ical outcome was supported by the ﬁndings in cross sectional
analysis that CD4+ T-lymphocyte telomere length correlated clo-
sely with increased ﬁbrosis stage, increased grade of portal tract
inﬂammation, prolonged prothrombin time and increased biliru-
bin, all factors that predict morbidity and mortality in patients
with chronic HCV infection [3]. In a prospective study, despite
the short duration of follow-up, patients with shorter CD4+ telo-
meres have outcomes inferior to those with longer telomeres,
with more frequent progression to the composite endpoint of
death, ﬁrst episode of hepatic decompensation or hepatocellular
carcinoma.
This study could not address whether HCV infection causes
accelerated telomere shortening, whether individuals with
shorter T-cell telomeres are pre-disposed to cirrhosis or whether
lifestyles associated with HCV infection affect telomere length.
Longitudinal follow-up is underway and may address these
issues. Similarly, we have restricted the investigations of the rela-
tionship of lymphocyte telomere length and clinical outcome to
HCV infection only. Previous studies have suggested that hepato-
cyte telomere shortening occurs in a variety of chronic liver dis-
eases [25,26]. We hypothesise that lymphocytic telomere length
shortening would occur in other chronic liver diseases, but no
data yet exists to support this.
Our data pose the intriguing question of why telomere short-
ening occurs in T-cells in chronic HCV infection. There is no evi-
dence of a failure to induce telomerase, an enzyme that maintains
telomere length, in peripheral lymphocytes (unpublished data).
The most likely explanation is chronic hepatic inﬂammation, with
attendant cytokine release, leading to a bystander effect upon
lymphocytes as observed in CMV infection [17] where both
CMV-speciﬁc and non-speciﬁc cells develop accelerated senes-
cence. One obvious issue is that of telomere length in HCV-spe-
ciﬁc cells. Multiple studies have demonstrated that such cells
are detected rarely in the periphery [27,28] and thus cannot
account for our ﬁndings. Their scarcity has also rendered it
impossible to analyse telomere length in HCV-speciﬁc CD8+ or
CD4+ populations with conﬁdence.
Global lymphocyte telomere shortening has been observed
previously and linked to poor clinical outcome in healthy
elderly individuals [9], particularly that due to infection.0 vol. 53 j 252–260
Unadjusted HR (95% CI) Age-adjusted HR (95% CI)
Cohort Endpoint
CD8+
CD45RO+ 
telomere 
p
CD4+
CD45RO+ 
telomere 
p Age (years) p
CD8+
CD45RO+ 
telomere 
p
CD4+
CD45RO+ 
telomere 
p
Overall
(n = 124)
Composite
0.96 
(0.93- 0.99) 
<0.001
0.93 
(0.91- 0.96) 
0.008     
1.10 
(1.04- 1.15) 
<0.001
0.96 
(0.93-1.00) 
<0.001
0.93 
(0.90- 0.96) 
0.03
Composite
0.96 
(0.92- 0.99) 
<0.001
0.94 
(0.91- 0.96) 
0.01
1.11 
(1.04- 1.19) 
0.002
0.96 
(0.93- 0.99) 
<0.001
0.93 
(0.90- 0.96) 
0.02
0.95 
(0.91-1.00)
0.04     
0.93 
(0.89- 0.98) 
0.003
1.05 
(0.94- 1.16) 
0.4
0.95 
(0.91-1.00)
0.05     
0.93 
(0.89- 0.98) 
0.003
Severe 
fibrosis
(n = 55)
HCC
0.97 
(0.92-1.01)
0.2     
0.94 
(0.90- 0.98) 
0.003
1.16 
(1.07- 1.26) 
<0.001
0.97 
(0.92-1.01)
0.1     
0.92 
(0.87- 0.97) 
0.003
Decompensation
Table 4. Demographic characteristics of interferon-treated cohort.
Whole cohort Failed to achieve SVR Achieved SVR
n 85 47 38
Age (years, mean ± SD) 52.3 ± 8.8 55.0 ± 8.9 49.7 ± 7.6
Sex (% male) 75.3 72.3 78.9
BMI 26.6 ± 5.3 27.5 ± 5.7 25.5 ± 4.5
Bilirubin (lmol/L, mean ± SD) 12.3 ± 6.6 12.2 ± 6.1 11.5 ± 6.8
ALT (IU/L, mean ± SD) 113.2 ± 81.9 112.7 ± 83.2 117.1 ± 85.7
PT (seconds, mean ± SD) 13.2 ± 1.4 13.2 ± 1.1 13.2 ± 1.7
Genotype 1 45.9% 53.2% 36.8%
2 11.8% 10.6% 13.2%
3 41.2% 36.2% 47.4%
4 1.1% 0% 2.6%
Viral Load (mean ± SD) 1.35  106 ± 6.99  106 2.31  106 ± 9.34  106 1.67  105 ± 2.54  105
% CMV antibody positive 51.0 51.1 50.0
Ishak score
Interface hepatitis (0 - 4) 1.8 ± 0.6 1.7 ± 0.5 1.8 ± 0.7
Conﬂuent necrosis (0 - 6) 0.1 ± 0.2 0.1 ± 0.3 0.0 ± 0.2
Lobular hepatitis (0 - 4) 2.2 ± 0.6 1.0 ± 0.5 2.3 ± 0.6
Portal inﬂammation (0 - 4) 2.2 ± 0.6 2.2 ± 0.6 2.2 ± 0.6
Fibrosis (0 - 6) 3.6 ± 1.5 3.9 ± 1.4 3.4 ± 1.5
Steatosis (0 - 3) 0.8 ± 0.8 1.0 ± 0.8 0.6 ± 0.8
Table 3. Unadjusted and adjusted Hazard Ratios (and 95% CI) for decompensation, development of HCC and a composite endpoint of death, decompensation or
development of HCC by CD8+CD45RO+ and CD4+CD45RO+ T-lymphocyte telomere length and age in whole viraemic cohort (n = 124) or subjects with severe ﬁbrosis
(n = 55).
Bold indicates signiﬁcant results.
Table 5. Predictors of SVR by multiple logistic regression analysis. Input variables were age, gender, ﬁbrosis group (mild (Ishak 0–3), severe (4–6)), viral genotype (2 and
3 versus 1 and 4), viral load, BMI, CD8+CD45RO+ and CD4+CD45RO+ lymphocyte telomere length. Non-signiﬁcant variables were removed by backward stepwise
regression.
Logistic regression Backward LR stepwise regression
Variable Comparison Wald OR (95% CI) p Comparison Wald OR (95% CI) p
Age - 0.72 0.97 (0.89, 1.05) 0.40
Sex Male vs. female 0.53 1.74 (0.39, 7.66) 0.47
Fibrosis Severe vs. Mild 3.03 0.18 (0.03, 1.24) 0.08
Genotype 2/3 vs. 1/4 1.90 2.17 (0.71, 6.89) 0.17
Viral load - 5.74 1.00 (1.00, 1.00) 0.02 - 5.58 1.00 (1.00, 1.00) 0.02
BMI - 0.007 1.00 (0.88, 1.12) 0.93
CD8+45RO+ telomere length - 0.09 1.01 (0.96, 1.06) 0.76
CD4+45RO+ telomere length - 2.59 1.06 (0.99, 1.14) 0.11 - 11.28 1.08 (1.03, 1.13) 0.001
Bold indicates signiﬁcant results.
JOURNAL OF HEPATOLOGYSimilarly, oligoclonality of the peripheral lymphocyte compart-
ment has been associated with premature ageing of the
immune system and increased morbidity [8]. Manfras et al.
demonstrated that increased oligoclonality of the peripheral
lymphocyte compartment was associated with poor responses
to antiviral therapy in chronic HCV [19] and that individuals
with increased CD8+ lymphocytes bearing the terminally differ-Journal of Hepatology 201entiated phenotype CD28CD57+ had impaired responses to
IFN-a [19].
Prospective study revealed that CD4+CD45RO+ lymphocyte
telomere lengths predicted the response to antiviral therapy in
chronic HCV infection, independent of age, sex, HCV genotype,
BMI and hepatic ﬁbrosis, all factors that have been identiﬁed pre-
viously as predicting the response to antiviral therapy [21,29].0 vol. 53 j 252–260 259
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Our ﬁndings suggest that individuals with mild disease, but short
telomeres should be considered for antiviral therapy at the earli-
est opportunity rather than adopting a conservative ‘watch and
wait’ approach.Funding
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